Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roundhill GLP-1 & Weight Loss ETF (NQ: OZEM )

26.63 +0.36 (+1.37%)
Streaming Delayed Price Updated: 9:45 AM EDT, Jun 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roundhill GLP-1 & Weight Loss ETF

ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments. 
Via Benzinga
Topics ETFs
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks. 
Via Benzinga
Topics ETFs
Tesla (TSLA) Stock Drops as Glass Lewis Urges Against Elon Musk’s Pay Package
Tesla stock is down on Tuesday as advisory firm Glass Lewis recommends TSLA shareholders vote against a massive pay package for Elon Musk. 
Via InvestorPlace
Campbell Soup Layoffs 2024: What to Know About New Campbell Job Cuts
Campbell Soup layoffs are coming for 415 workers as the company plans to close down one factory and shift operations at others. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them. 
Via InvestorPlace
Topics ETFs
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
Weight loss drugs get the new parody treatment in a "South Park" streaming special. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." 
Via Benzinga
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.